Company news

Cognition Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023

August 1, 2023

Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD

July 10, 2023

Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease

July 4, 2023

Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

June 27, 2023

Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023

June 26, 2023

Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches

June 19, 2023

Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences

June 1, 2023

Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC

May 22, 2023

Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

May 17, 2023

Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

April 30, 2023

Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

April 18, 2023

Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

April 11, 2023

Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes

March 27, 2023

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies

March 26, 2023

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

March 22, 2023

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

March 15, 2023

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

March 14, 2023

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

February 21, 2023

Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

February 8, 2023

Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"

December 20, 2022

First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812

December 14, 2022

Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD

November 27, 2022

Cognition Therapeutics Announces Closing of Public Offering

November 14, 2022

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

Cognition Therapeutics Announces Pricing of Public Offering

November 9, 2022

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

October 11, 2022

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

October 10, 2022

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

September 26, 2022

Cognition Therapeutics Announces Participation in September Investment Conferences

September 5, 2022

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 8, 2022

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

June 22, 2022

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 10, 2022

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

May 3, 2022

Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD

May 2, 2022

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

April 24, 2022

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

April 5, 2022

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

March 29, 2022

Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results

March 21, 2022

Cognition Therapeutics Announces Participation in March Investment Conferences

March 7, 2022

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease

January 3, 2022

Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation

November 29, 2021

Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights

November 17, 2021

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering

November 14, 2021

Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

November 2, 2021

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

October 7, 2021

← Newer news releases

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.